293 related articles for article (PubMed ID: 32907364)
1. Targeted Modulation of FAK/PI3K/PDK1/AKT and FAK/p53 Pathways by Cucurbitacin B for the Antiproliferation Effect Against Human Cholangiocarcinoma Cells.
Klungsaeng S; Kukongviriyapan V; Prawan A; Kongpetch S; Senggunprai L
Am J Chin Med; 2020; 48(6):1475-1489. PubMed ID: 32907364
[TBL] [Abstract][Full Text] [Related]
2. Cucurbitacin B Diminishes Metastatic Behavior of Cholangiocarcinoma Cells by Suppressing Focal Adhesion Kinase.
Kaewmeesri P; Kukongviriyapan V; Prawan A; Kongpetch S; Senggunprai L
Asian Pac J Cancer Prev; 2021 Jan; 22(1):219-225. PubMed ID: 33507702
[TBL] [Abstract][Full Text] [Related]
3. Cucurbitacin B induces mitochondrial-mediated apoptosis pathway in cholangiocarcinoma cells via suppressing focal adhesion kinase signaling.
Klungsaeng S; Kukongviriyapan V; Prawan A; Kongpetch S; Senggunprai L
Naunyn Schmiedebergs Arch Pharmacol; 2019 Mar; 392(3):271-278. PubMed ID: 30470919
[TBL] [Abstract][Full Text] [Related]
4. Anti-metastatic Potential of Natural Triterpenoid Cucurbitacin B Against Cholangiocarcinoma Cells by Targeting Src Protein.
Kaewmeesri P; Pocasap P; Kukongviriyapan V; Prawan A; Kongpetch S; Senggunprai L
Integr Cancer Ther; 2022; 21():15347354221124861. PubMed ID: 36154723
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of celastrol by inhibition of proliferation, invasion, and migration in cholangiocarcinoma via PTEN/PI3K/Akt pathway.
Zhu B; Wei Y
Cancer Med; 2020 Jan; 9(2):783-796. PubMed ID: 31957323
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
Gene; 2019 May; 698():50-60. PubMed ID: 30822475
[TBL] [Abstract][Full Text] [Related]
7. Cucurbitacin-I inhibits Aurora kinase A, Aurora kinase B and survivin, induces defects in cell cycle progression and promotes ABT-737-induced cell death in a caspase-independent manner in malignant human glioma cells.
Premkumar DR; Jane EP; Pollack IF
Cancer Biol Ther; 2015; 16(2):233-43. PubMed ID: 25482928
[TBL] [Abstract][Full Text] [Related]
8. Derrischalcone suppresses cholangiocarcinoma cells through targeting ROS-mediated mitochondrial cell death, Akt/mTOR, and FAK pathways.
Wandee J; Srinontong P; Prawan A; Senggunprai L; Kongpetch S; Yenjai C; Kukongviriyapan V
Naunyn Schmiedebergs Arch Pharmacol; 2021 Sep; 394(9):1929-1940. PubMed ID: 34086099
[TBL] [Abstract][Full Text] [Related]
9. Yin Yang 1-induced LINC00667 up-regulates pyruvate dehydrogenase kinase 1 to promote proliferation, migration and invasion of cholangiocarcinoma cells by sponging miR-200c-3p.
Li J; Guan C; Hu Z; Liu L; Su Z; Kang P; Jiang X; Cui Y
Hum Cell; 2021 Jan; 34(1):187-200. PubMed ID: 33040228
[TBL] [Abstract][Full Text] [Related]
10. The Effect of the EGFR - Targeting Compound 3-[(4-Phenylpyrimidin-2-yl) Amino] Benzene-1-Sulfonamide (13f) against Cholangiocarcinoma Cell Lines.
Samatiwat P; Tabtimmai L; Suphakun P; Jiwacharoenchai N; Toviwek B; Kukongviriyapan V; Gleeson MP; Choowongkomon K
Asian Pac J Cancer Prev; 2021 Feb; 22(2):381-390. PubMed ID: 33639651
[TBL] [Abstract][Full Text] [Related]
11. Sulfated Galactans from Red Seaweed Gracilaria fisheri Target EGFR and Inhibit Cholangiocarcinoma Cell Proliferation.
Sae-Lao T; Tohtong R; Bates DO; Wongprasert K
Am J Chin Med; 2017; 45(3):615-633. PubMed ID: 28385079
[TBL] [Abstract][Full Text] [Related]
12. Tip60 Suppresses Cholangiocarcinoma Proliferation and Metastasis via PI3k-AKT.
Zhang Y; Ji G; Han S; Shao Z; Lu Z; Huo L; Zhang J; Yang R; Feng Q; Shen H; Wang H; Li X
Cell Physiol Biochem; 2018; 50(2):612-628. PubMed ID: 30308494
[TBL] [Abstract][Full Text] [Related]
13. Extracellular taurine induces angiogenesis by activating ERK-, Akt-, and FAK-dependent signal pathways.
Baek YY; Cho DH; Choe J; Lee H; Jeoung D; Ha KS; Won MH; Kwon YG; Kim YM
Eur J Pharmacol; 2012 Jan; 674(2-3):188-99. PubMed ID: 22130357
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo Anti-Tumor Effects of Pan-HER Inhibitor Varlitinib on Cholangiocarcinoma Cell Lines.
Dokduang H; Jamnongkarn W; Promraksa B; Suksawat M; Padthaisong S; Thanee M; Phetcharaburanin J; Namwat N; Sangkhamanon S; Titapun A; Khuntikeo N; Klanrit P; Loilome W
Drug Des Devel Ther; 2020; 14():2319-2334. PubMed ID: 32606601
[TBL] [Abstract][Full Text] [Related]
15. GSK‑3β inhibition promotes doxorubicin‑induced apoptosis in human cholangiocarcinoma cells via FAK/AKT inhibition.
Li L; Xiang Y; Zeng Y; Xiao B; Yu W; Duan C; Xia X; Zhang T; Zeng Y; Liu Y; Dai R
Mol Med Rep; 2020 Nov; 22(5):4432-4441. PubMed ID: 33000181
[TBL] [Abstract][Full Text] [Related]
16. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways.
Jaidee R; Kukongviriyapan V; Senggunprai L; Prawan A; Jusakul A; Laphanuwat P; Kongpetch S
Life Sci; 2022 May; 296():120427. PubMed ID: 35218764
[TBL] [Abstract][Full Text] [Related]
18. A PLCB1-PI3K-AKT Signaling Axis Activates EMT to Promote Cholangiocarcinoma Progression.
Liang S; Guo H; Ma K; Li X; Wu D; Wang Y; Wang W; Zhang S; Cui Y; Liu Y; Sun L; Zhang B; Xin M; Zhang N; Zhou H; Liu Y; Wang J; Liu L
Cancer Res; 2021 Dec; 81(23):5889-5903. PubMed ID: 34580062
[TBL] [Abstract][Full Text] [Related]
19. High expression of ErbB2 contributes to cholangiocarcinoma cell invasion and proliferation through AKT/p70S6K.
Treekitkarnmongkol W; Suthiphongchai T
World J Gastroenterol; 2010 Aug; 16(32):4047-54. PubMed ID: 20731018
[TBL] [Abstract][Full Text] [Related]
20. Activation of the PI3K-AKT signaling pathway by SPARC contributes to the malignant phenotype of cholangiocarcinoma cells.
Deng S; Zhang L; Li J; Jin Y; Wang J
Tissue Cell; 2022 Jun; 76():101756. PubMed ID: 35217388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
